PFIZER INC Sale and Leaseback Transaction, Gain (Loss), Net
PFIZER INC (PFE) reported Sale and Leaseback Transaction, Gain (Loss), Net of $53.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:SaleAndLeasebackTransactionGainLossNet · last filed 2026-02-26
- PFIZER INC sale and leaseback transaction, gain (loss), net for the quarter ending 2019-12-31 was $61.00M.
- PFIZER INC sale and leaseback transaction, gain (loss), net for fiscal 2025 was $53.00M.
- PFIZER INC sale and leaseback transaction, gain (loss), net for fiscal 2024 was -$29.00M, a 159.18% decline from fiscal 2023.
- PFIZER INC sale and leaseback transaction, gain (loss), net for fiscal 2023 was $49.00M.
- PFIZER INC sale and leaseback transaction, gain (loss), net for fiscal 2022 was -$11.00M.
| Period end | Sale and Leaseback Transaction, Gain (Loss), Net 3 month | Sale and Leaseback Transaction, Gain (Loss), Net 9 month | Sale and Leaseback Transaction, Gain (Loss), Net 12 month | Sale and Leaseback Transaction, Gain (Loss), Net 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $53.00M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | -$29.00M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $49.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$11.00M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | -$1.00M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $3.00M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $29.00M 10-K · filed 2022-02-24 | -$29.00M 10-K · filed 2020-02-27 | |
| 2019-09-29 | -$32.00M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |